-
American heart journal · Jun 2012
Randomized Controlled Trial Multicenter StudyIntraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.
- Holger Thiele, Gerhard Schuler, Franz-Josef Neumann, Jörg Hausleiter, Hans-Georg Olbrich, Bettina Schwarz, Marcus Hennersdorf, Klaus Empen, Georg Fuernau, Steffen Desch, Suzanne de Waha, Ingo Eitel, Rainer Hambrecht, Michael Böhm, Volkhard Kurowski, Bernward Lauer, Hans-Heinrich Minden, Hans-Reiner Figulla, Rüdiger C Braun-Dullaeus, Ruth H Strasser, Kristin Rochor, Sebastian K G Maier, Helge Möllmann, Steffen Schneider, Henning Ebelt, Karl Werdan, and Uwe Zeymer.
- University of Leipzig-Heart Center, Leipzig, Germany. thielh@medizin.uni-leipzig.de
- Am. Heart J. 2012 Jun 1;163(6):938-45.
BackgroundIn current guidelines, intraaortic balloon pumping (IABP) is considered a class 1 indication in cardiogenic shock complicating acute myocardial infarction. However, evidence is mainly based on retrospective or prospective registries with a lack of randomized clinical trials. Therefore, IABP is currently only used in 20% to 40% of cardiogenic shock cases. The hypothesis of this trial is that IABP in addition to early revascularization by either percutaneous coronary intervention or coronary artery bypass grafting will improve clinical outcome of patients in cardiogenic shock.Study DesignThe IABP-SHOCK II study is a 600-patient, prospective, multicenter, randomized, open-label, controlled trial. The study is designed to compare the efficacy and safety of IABP versus optimal medical therapy on the background of early revascularization by either percutaneous coronary intervention or coronary artery bypass grafting. Patients will be randomized in a 1:1 fashion to 1 of the 2 treatments. The primary efficacy end point of IABP-SHOCK II is 30-day all-cause mortality. Secondary outcome measures, such as hemodynamic, laboratory, and clinical parameters, will serve as surrogate end points for prognosis. Furthermore, an intermediate and long-term follow-up at 6 and 12 months will be performed. Safety will be assessed, by the GUSTO bleeding definition, peripheral ischemic complications, sepsis, and stroke.ConclusionsThe IABP-SHOCK II trial addresses important questions regarding the efficacy and safety of IABP in addition to early revascularization in patients with cardiogenic shock complicating myocardial infarction.Copyright © 2012 Mosby, Inc. All rights reserved.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.